0001209191-22-035688.txt : 20220609
0001209191-22-035688.hdr.sgml : 20220609
20220609211953
ACCESSION NUMBER: 0001209191-22-035688
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220607
FILED AS OF DATE: 20220609
DATE AS OF CHANGE: 20220609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Hunter C
CENTRAL INDEX KEY: 0001636385
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37722
FILM NUMBER: 221007456
MAIL ADDRESS:
STREET 1: C/O GENESEE & WYOMING INC.
STREET 2: 20 WEST AVENUE
CITY: DARIEN
STATE: CT
ZIP: 06820
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aeglea BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001636282
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464312787
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 805 LAS CIMAS PARKWAY
STREET 2: SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: (512) 942-2935
MAIL ADDRESS:
STREET 1: 805 LAS CIMAS PARKWAY
STREET 2: SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78746
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-07
0
0001636282
Aeglea BioTherapeutics, Inc.
AGLE
0001636385
Smith Hunter C
C/O AEGLEA BIOTHERAPEUTICS, INC.
805 LAS CIMAS PARKWAY, SUITE 100
AUSTIN
TX
78746
1
0
0
0
Director Stock Option (right to buy)
0.73
2022-06-07
4
A
0
43000
0.00
A
2032-06-06
Common Stock
43000
43000
D
The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Exhibit 24 - Power of Attorney
/s/ James Kastenmayer, by power of attorney
2022-06-09
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Jonathan Alspaugh, Steven Weber and James Kastenmayer, and each of
them, as the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of Aeglea BioTherapeutics, Inc. (the "Company"), any and all
Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be
filed by the undersigned in accordance with Section 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect
to transactions in the Company's securities;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID, or Form
3, 4 or 5 report and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or similar
authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in his or
her discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary, and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or his or her
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted. The
undersigned acknowledges that no such attorney-in-fact, in serving in such
capacity at the request of the undersigned, is hereby assuming, nor is the
Company hereby assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 9th day of June, 2022.
/s/ Hunter Smith
Name: Hunter Smith